Nov 22, 2021 / 01:30PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Chimerix Conference Call. I would now like to introduce your host for today's call, Will O'Connor of Stern Investor Relations. Please proceed.
Will OâConnor - Stern Investor Relations, Inc. - Associate
Thank you, operator. Good morning, everyone, and welcome to the Chimerix ONC201 data conference call. On Friday, we issued a press release announcing the data and analysis of ONC201 in Recurrent H3 K27M-mutant Diffuse Midline Glioma. These data were then presented over the weekend at the Society for Neuro Oncology annual meeting. You can access this press release as well as the slide presentation that we'll be reviewing this morning in the Investors section of the Chimerix website.
With me on today's call are Dr. Isabella Arrillaga, Director of Neuro Oncology Clinical Trials at Massachusetts General Hospital Cancer Center; Mike Sherman, President and Chief Executive Officer of Chimerix; and Dr. Allen Melemed, Chief Medical Officer of Chimerix. Dr. Josh Allen, Chief Technology Officer
Chimerix Inc to Discuss Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma Call Transcript
Nov 22, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers